Correction: Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.

Robbins, Hilary A; Alcala, Karine; Swerdlow, Anthony J; Schoemaker, Minouk J; Wareham, Nick; Travis, Ruth C; Crosbie, Philip A J; Callister, Matthew; Baldwin, David R; Landy, Rebecca; Johansson, Mattias

Robbins, Hilary A; Alcala, Karine; Swerdlow, Anthony J; Schoemaker, Minouk J; Wareham, Nick; Travis, Ruth C; Crosbie, Philip A J; Callister, Matthew; Baldwin, David R; Landy, Rebecca; Johansson, Mattias.

Afiliação

Robbins HA; International Agency for Research on Cancer, Lyon, France. robbinsh@iarc.fr.
Alcala K; International Agency for Research on Cancer, Lyon, France.
Swerdlow AJ; The Institute of Cancer Research, London, UK.
Schoemaker MJ; The Institute of Cancer Research, London, UK.
Wareham N; University of Cambridge, Cambridge, UK.
Travis RC; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Crosbie PAJ; University of Manchester, Manchester, UK.
Callister M; Leeds Teaching Hospitals, Leeds, UK.
Baldwin DR; Nottingham University Hospitals and University of Nottingham, Nottingham, UK.
Landy R; Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Johansson M; International Agency for Research on Cancer, Lyon, France.

Br J Cancer ; 125(2): 305, 2021 Jul.

Article em En | MEDLINE | ID: mdl-34002041

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies / Screening_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google